Skip to main content

Table 4 Anti-CCP titer decrease in adalimumab treated patients: correlation with the clinical response to treatment

From: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

ACR response, week 24

Week 0

Week 24

P

ACR response, week 48

Week 0

Week 48

P

<20% (n = 6)

118.4 ± 34.9

111.8 ± 48.8

n.s.

<20% (n = 3)

107 ± 14.1

68.4 ± 23.3

n.d.

ACR 20 (n = 21)

111.5 ± 45.9

104.3 ± 48.5

n.s.

ACR 20 (n = 21)

121.8 ± 48.2

88.6 ± 52.6

0.001

ACR 50 (n = 16)

121.9 ± 45.1

93.9 ± 46.4

0.001

ACR 50 (n = 13)

119.6 ± 45.8

73.5 ± 36.2

0.001

ACR 70 (n = 3)

126.8 ± 51.9

85.9 ± 43.5

n.d.

ACR 70 (n = 9)

105.3 ± 37.7

65.3 ± 35.5

0.003

  1. 46 anti-CCP-positive patients at baseline were included in the evaluation. Results are means ± SD. CCP, cyclic citrullinated peptide; n.d., not done; n.s., not significant.